Aoife Brennan - 06 Jan 2026 Form 4 Insider Report for Climb Bio, Inc. (CLYM)

Reporting relationship: President and CEO, Director
Issuer ticker: CLYM
Reported as of: 06 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jan 2026, 16:05:18 UTC
Prior SEC filing: 01 Jul 2025
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Chandra Adams, as Attorney-in-Fact

Key filing fact

Aoife Brennan filed Form 4 for Climb Bio, Inc. (CLYM) on 08 Jan 2026.

Key facts

This page summarizes Aoife Brennan's Form 4 filing for Climb Bio, Inc. (CLYM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Jan 2026, 16:05.

Change

Previous filing in this sequence was filed on 01 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001714563 Primary reporting owner

Brennan Aoife

Relationship: President and CEO, Director
Address: C/O CLIMB BIO, INC., 20 WILLIAM STREET, SUITE 145, WELLESLEY HILLS
Signature: /s/ Chandra Adams, as Attorney-in-Fact
Signature date: 08 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLYM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +700,000
Change %
Price: $0.000000
Shares after: 700,000
Date: 06 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 700,000
Exercise price: $3.81
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was granted on January 6, 2026 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 6, 2030, subject to the Reporting Person's continued service.